Does TREPROSTINIL Cause Injection site discolouration? 56 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 56 reports of Injection site discolouration have been filed in association with TREPROSTINIL (TYVASO). This represents 0.1% of all adverse event reports for TREPROSTINIL.
56
Reports of Injection site discolouration with TREPROSTINIL
0.1%
of all TREPROSTINIL reports
3
Deaths
29
Hospitalizations
How Dangerous Is Injection site discolouration From TREPROSTINIL?
Of the 56 reports, 3 (5.4%) resulted in death, 29 (51.8%) required hospitalization, and 1 (1.8%) were considered life-threatening.
Is Injection site discolouration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 56 reports have been filed with the FAERS database.
What Other Side Effects Does TREPROSTINIL Cause?
Dyspnoea (16,348)
Headache (14,051)
Diarrhoea (11,335)
Nausea (10,320)
Cough (8,945)
Fatigue (7,440)
Dizziness (7,405)
Infusion site pain (5,169)
Vomiting (5,097)
Death (4,764)
What Other Drugs Cause Injection site discolouration?
ETANERCEPT (1,846)
DUPILUMAB (779)
CERTOLIZUMAB PEGOL (597)
ADALIMUMAB (554)
EVOLOCUMAB (476)
GLATIRAMER (270)
EXENATIDE (266)
TERIPARATIDE (249)
ASFOTASE ALFA (243)
ENBREL (231)
Which TREPROSTINIL Alternatives Have Lower Injection site discolouration Risk?
TREPROSTINIL vs TREPROSTINIL DIOLAMINE
TREPROSTINIL vs TRETINOIN
TREPROSTINIL vs TRIAMCINOLONE
TREPROSTINIL vs TRIAMCINOLONE ACETONIDE
TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE